
OTLK Stock Forecast & Price Target
OTLK Analyst Ratings
Bulls say
Outlook Therapeutics is a clinical-stage biopharmaceutical company that has recently achieved European commercial launch of its product LYTENAVA (bevacizumab gamma) for the treatment of wet AMD in U.K. and Germany and plans to launch in Switzerland in 2027. While the company has reported revenue of $(1) million in Q1 of FY26, it is expected to grow significantly with its product launch. However, risks to share price target include balance sheet and liquidity risks, failure to obtain regulatory approvals and suitable reimbursement, and competition in the eye disease therapy space.
Bears say
Outlook Therapeutics is a clinical-stage biopharmaceutical company with only one main candidate, ONS-5010, currently in development for the treatment of wet age-related macular degeneration (wet AMD) and other eye diseases. However, the company has faced challenges with FDA approval for its product and may need to conduct further studies, which could require additional capital and result in share dilution for shareholders. Additionally, Outlook faces competition from well-established companies in the eye disease therapy space, potentially limiting their market potential. All of these factors contribute to a negative outlook for the company's future financial performance.
This aggregate rating is based on analysts' research of Outlook Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
OTLK Analyst Forecast & Price Prediction
Start investing in OTLK
Order type
Buy in
Order amount
Est. shares
0 shares